The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is uncertainty around the economic burden of NAFLD. We constructed a steady‐state prevalence model to quantify this burden in the United States and Europe. Five models were constructed to estimate the burden of NAFLD in the United States and four European countries. Models were built using a series of interlinked Markov chains, each representing age increments of the NAFLD and the general populations. Incidence and remission rates were calculated by calibrating against real‐world prevalence rates. The data were validated using a computerized disease model called DisMod II. NAFLD patients transitioned between nine health states (nonalcoholic fatty liver, nonalcoholic steatohepatitis [NASH], NASH‐fibrosis, NASH‐compensated cirrhosis, NASH‐decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, post‐liver transplant, and death). Transition probabilities were sourced from the literature and calibrated against real‐world data. Utilities were obtained from NAFLD patients using the Short Form‐6D. Costs were sourced from the literature and local fee schedules. In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient). In the Europe‐4 countries (Germany, France, Italy, and United Kingdom), there are ∼52 million people with NAFLD with an annual cost of about €35 billion (from €354 to €1,163 per patient). Costs are highest in patients aged 45‐65. The burden is significantly higher when societal costs are included. Conclusion: The analysis quantifies the enormity of the clinical and economic burdens of NAFLD, which will likely increase as the incidence of NAFLD continues to rise. (H epatology 2016;64:1577‐1586)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · cited 5×
“In addition to cirrhosis, there is mounting evidence that NAFLD is an important risk factor for HCC.(12,13) Although cirrhosis in NASH has been indicated as a risk factor for HCC, there is some evidence to suggest that NAFLD patients without cirrhosis may also be at risk of developing HCC.(14) Finally, the clinical ou…”
BackgroundMethodInfluentialSelf-citationYounossi, Z. M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., & Goodman, Z. (2011) · Hepatology · doi:10.1002/hep.24268 · Cited by 638
Self-citationThe Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
Sayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
Self-citationNonalcoholic fatty liver disease in patients with type 2 diabetes
Younossi, Z. M., Gramlich, T., Matteoni, C. A., Boparai, N., & McCullough, A. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00014-x · Cited by 443
Self-citationEpidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Self-citationCardiovascular Risk Factors and the Metabolic Syndrome in Pediatric Nonalcoholic Fatty Liver Disease
Schwimmer, J. B., Pardee, P. E., Lavine, J. E., Blumkin, A. K., & Cook, S. (2008) · Circulation · doi:10.1161/circulationaha.107.739920 · Cited by 402
A generic model for the assessment of disease epidemiology: the computational basis of DisMod II
Barendregt, J. J., van Oortmarssen, G. J., Vos, T., & Murray, C. J. (2003) · Population Health Metrics · doi:10.1186/1478-7954-1-4 · Cited by 402
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., Goodman, Z., & Younossi, Z. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.007 · Cited by 342
Self-citationHealth-related quality of life in chronic liver disease: the impact of type and severity of disease
Younossi, Z. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02519-9 · Cited by 335
Self-citationYounossi, Z., & Henry, L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.005 · Cited by 334 · cited 5×
“Although NASH represents the minority (10%-20%) of patients with NAFLD, the NASH subtype can potentially progress to advanced liver disease, leading to cirrhosis, liver-related mortality, and hepatocellular carcinoma (HCC).((1-5)) Despite NASH being a more progressive type of NAFLD, the non-NASH type of NAFLD still ca…”
BackgroundMethodResultInfluentialSelf-citationBennett, W. G., Inoue, Y., Beck, J. R., Wong, J. B., Pauker, S. G., & Davis, G. L. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00001 · Cited by 315
Spanish recommendations on economic evaluation of health technologies
López-Bastida, J., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., & Puig-Junoy, J. (2010) · The European Journal of Health Economics · doi:10.1007/s10198-010-0244-4 · Cited by 240
Calibrating Models in Economic Evaluation: A Seven-Step Approach
Vanni, T., Karnon, J., Madan, J., White, R. G., Edmunds, W. J., Foss, A. M., & Legood, R. (2011) · PharmacoEconomics · doi:10.2165/11584600-000000000-00000 · Cited by 173
McAdam-Marx, C., McGarry, L. J., Hane, C. A., Biskupiak, J., Deniz, B., & Brixner, D. I. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.7.531 · Cited by 167
Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review
McLernon, D. J., Dillon, J., & Donnan, P. T. (2008) · Medical Decision Making · doi:10.1177/0272989x08315240 · Cited by 165
Dienstag, J. L., Ghany, M. G., Morgan, T. R., Di Bisceglie, A. M., Bonkovsky, H. L., Kim, H.-Y., Seeff, L. B., Szabo, G., Wright, E. C., Sterling, R. K., et al. (2011) · Hepatology · doi:10.1002/hep.24370 · Cited by 165
Golabi, P., Otgonsuren, M., Cable, R., Felix, S. C., Koenig, A. B., Sayıner, M., & Younossi, Z. M. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0420-z · Cited by 151
Self-citationYounossi, Z. M., Park, H., Saab, S., Ahmed, A., Dieterich, D. T., & Gordon, S. C. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13081 · Cited by 118
Self-citationEconomic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
Younossi, Z. M., & Henry, L. L. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0316-5 · Cited by 92
Self-citationHsu, P. C., Federico, C. A., Krajden, M., Yoshida, E. M., Bremner, K. E., Anderson, F., Weiss, A. A., & Krahn, M. D. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06813.x · Cited by 81
Sayiner, M., Otgonsuren, M., Cable, R., Younossi, I., Afendy, M., Golabi, P., Henry, L., & Younossi, Z. M. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000567 · Cited by 76
Self-citationChawla, K. S., Talwalkar, J. A., Keach, J. C., Malinchoc, M., Lindor, K. D., & Jorgensen, R. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2015-000069 · Cited by 64
Otgonsuren, M., Stepanova, M., Gerber, L. H., & Younossi, Z. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2446-3 · Cited by 60
Self-citationThe use of models in the estimation of disease epidemiology.
Kruijshaar, M. E., Barendregt, J. J., & Hoeymans, N. (2002) · Europe PMC (PubMed Central) · Cited by 59
Younossi, Z. M., Zheng, L., Stepanova, M., Henry, L. L., Venkatesan, C., & Mishra, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000071 · Cited by 49
Self-citationCost‐effectiveness of sofosbuvir in the treatment of patients with hepatitis C
Leleu, H., Blachier, M., & Rosa, I. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12311 · Cited by 44
Lizán, L., Dilla, T., Paz, S., Garrido, P., Avendaño, C., Cruz, J. J., Espinosa, J., & Sacristán, J. A. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s93760 · Cited by 29
van Meer, S., van Erpecum, K. J., Sprengers, D., Klümpen, H., Jansen, P. L. M., IJzermans, J. N. M., Siersema, P. D., de Man, R. A., & Verheij, J. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000641 · Cited by 21
Stewart, G., Eddowes, L. A., Hamerslag, L., & Kusel, J. (2014) · Value in Health · doi:10.1016/j.jval.2014.03.041 · Cited by 17
Long-Term Improvement in Health-Related Quality of Life After Orthotopic Liver Transplantation
Dan, A. A., & Younossi, Z. M. (2008) · Liver Transplantation · doi:10.1002/lt.21551 · Cited by 11
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Metadata
- Authors
- Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R.
- Venue
- Hepatology
- Published
- 2016-09-26
- Volume
- 64
- Issue
- 5
- Pages
- 1577-1586
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2508708811
- Cited by
- 1,285
- References
- 41
- FWCI
- 82.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.